Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2013

Nov 7, 2013

30583_dirs_2013-11-07_eaf7b2f4-8de3-49b3-861f-efe49ebde670.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-11-05

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-11-05 Common Stock M 5000 $12.99 Acquired 50740 Indirect
2013-11-05 Common Stock S 5000 $62.3558 Disposed 45740 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-11-05 Stock Option (right to buy Common Stock) $12.99 M 5000 Disposed 2016-05-10 Common Stock (5000) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10000 Indirect
Common Stock 10000 Indirect
Common Stock 10000 Indirect
Common Stock 10000 Indirect
Common Stock 20000 Indirect

Footnotes

F1: Transaction made pursuant to a Rule 10b5-1 trading plan executed on February 26, 2013.

F2: The reporting person and his spouse act as trustees for the Bienaime Family Trust.

F3: The price in column 4 is a weighted average price. The price actually received ranged from $61.74 to $62.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at eachprice within the range.

F4: The reporting person's spouse is trustee of each child's trust.

F5: Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.

F6: Reflects number of stock options outstanding after the transaction from this specific stock option grant.